L. Weiler, N. Poulalhon, A. Slama
Nov 1, 2016
Citations
0
Influential Citations
14
Citations
Quality indicators
Journal
British Journal of Dermatology
Abstract
anti-inflammatory activity that has proven efficacy as a treatment for HS, reducing the pain from inflammatory nodules and shortening abscess duration. Resorcinol can cause hyperpigmentation, skin irritation and peeling, but these local sideeffects are usually well tolerated by the patients. The peeling effect appears with concentrations > 10%. Resorcinol is classified by the U.S. Food and Drug Administration as a category C drug, therefore pregnancy is contraindicated during and 1 month after the treatment. A surgical approach in PS is the treatment of choice, but is often associated with considerable morbidity, leading some patients to request a more conservative treatment. Topical resorcinol 15% may be useful for these patients as it is associated with only limited morbidity such as slight peeling of the treated area. Topical application appears better tolerated than phenolization of lesions. Recurrence after stopping topical treatment may occur, but the treatment offers the possibility of self-management, which may be useful to more than just those who reject surgery. To the best of our knowledge, this is the first report of PS treated with topical resorcinol 15% and monitored with high-frequency B-mode ultrasound.